Personalized Cancer Therapy
Biosimulation Predicts
The most efficacious chemotherapy
The most effective targeted therapy
The most beneficial immunotherapy
Synergistic therapy combinations
Radiotherapy sensitivity or resistance
Every patient's tumor has a unique mutation profile
Standard care guidelines only
consider one mutation at a
time, resulting in low response
rates across cancer types
Treatment guidelines do
not consider mutational
interactions that often cause
drug resistance
Genome sequencing technology
has improved significantly but
today's analysis of the output
is inadequate
Current treatment guidelines typically
target one mutation with one drug, resulting in
low response rates across cancer types
Mutation
Enasidenib
Skipping Mutation
Capmatinib
Mutation
Pembrolizumab
Why biosimulate cancer
therapy responses?

Know response before treatment
Select personalized therapies
Avoid ineffective treatments
Improve patient outcomes
How does personalized therapy biosimulation work?

Biosimulate a patient’s multi-omic profile to predict and rank individual patient responses to millions
of drug combinations by identifying oncotecture master regulators, mechanisms of resistance and
conducting signaling pathway impact analysis.
Therapy biosimulation reports predict each
patient's unique response to cancer treatments

SINGULA™
Predicts personalized response to Standard Care therapies for front-line patients
Download Sample ReportVENTURA™
Predicts and ranks personalized response to combinations of
FDA-approved drugs including off-label and non-oncology drugs for refractory patients

Cellworks biosimulation predictions proven
accurate across indications
myCare-101 Clinical Trial Process

Who can participate in myCare-101?
Physicians treating patients utilizing NGS reports for any of the listed
cancer indications can participate
- Bladder
- Bone
- Brain
- Breast
- Esophagus and Stomach
- Extragonadal Germinal Cell Tumors
- Genital Tract, Lower - Female
- Genital Tract, Lower - Male
- Head and Neck
- Kidney
- Large Intestine and Anus
- Leukemia
- Liver and Bile Duct
- Lung and Bronchus
- Lymphoma - Hodgkin
- Lymphoma - Non-Hodgkin
- Melanoma
- Mesothelioma
- Myelodysplastic Syndrome
- Myeloma
- Myeloproliferative Disease
- Ovary and Fallopian Tube
- Pancreas
- Prostate
- Skin
- Small Intestine
- Soft Tissue
- Testes
- Thymus
- Urothelial Carcinoma
- Uterus
- Cancer of Unknown Primary
- Bladder
- Bone
- Brain
- Breast
- Esophagus and Stomach
- Extragonadal Germinal Cell Tumors
- Genital Tract, Lower - Female
- Genital Tract, Lower - Male
- Head and Neck
- Kidney
- Large Intestine and Anus
- Leukemia
- Liver and Bile Duct
- Lung and Bronchus
- Lymphoma - Hodgkin
- Lymphoma - Non-Hodgkin
- Melanoma
- Mesothelioma
- Myelodysplastic Syndrome
- Myeloma
- Myeloproliferative Disease
- Ovary and Fallopian Tube
- Pancreas
- Prostate
- Skin
- Small Intestine
- Soft Tissue
- Testes
- Thymus
- Urothelial Carcinoma
- Uterus
- Cancer of Unknown Primary
Supported NGS Report Vendors
Sema4
Foundation Medicine
Caris
Tempus
MSK-IMPACT
Illumina

Learn more about the Cellworks
myCare-101 Clinical Trial
RESOURCES
Information, publications and white papers at your fingertips